GlaxoSmithKline Biologicals has signed a licensing agreement for a nicotine vaccine candidate currently in the first of two phase III …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

